Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily vs Pulse Alfacalcidol for SHPT in Hemodialysis
NCT02895061Completed
- Sponsor
- Phramongkutklao College of Medicine and Hospital
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of alfacalcidol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Phramongkutklao College of Medicine and Hospital. Primary endpoint: Difference of the mean PTH reduction at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
alfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02895061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895061.